Nuclear medicine is a medical specialty which uses radioactive tracers to diagnose and treat disease. Specially designed cameras allow doctors to track the circulation, uptake and excretion of these radioactive tracers. Garnering a CAGR of 10.4% from 2022 to 2028, the global nuclear medicine & radiopharmaceuticals market is projected to reach worth of USD 17,878 million by 2028-end, according to a new report The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global nuclear medicine & radiopharmaceuticals market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the nuclear medicine & radiopharmaceuticals industry. This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, and region. The global market for nuclear medicine & radiopharmaceuticals can be segmented by product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. The diagnostic radiopharmaceuticals segment held the largest share of the global nuclear medicine & radiopharmaceuticals market in 2021 and is anticipated to hold its share during the forecast period. Nuclear medicine & radiopharmaceuticals market is further segmented by application: bone metastasis, cardiology, endocrine tumor, hyperthyroidism, lymphoma, oncology, others. Based on region, the nuclear medicine & radiopharmaceuticals market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW). By product: - diagnostic radiopharmaceuticals - therapeutic radiopharmaceuticals By application: - bone metastasis - cardiology - endocrine tumor - hyperthyroidism - lymphoma - oncology - others By region: - Asia Pacific - Europe - North America - Rest of the World (RoW) The global nuclear medicine & radiopharmaceuticals market report offers detailed information on several market vendors, including Australian Nuclear Science and Technology Organisation (ANSTO), Bracco S.p.A., Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., IBA Molecular (IBAM), IRE - IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings, Inc., Nordion Inc, NTP Radioisotopes SOC Ltd., among others. *REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES Historical & Forecast Period This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year. Scope of the Report - To analyze and forecast the market size of the global nuclear medicine & radiopharmaceuticals market. - To classify and forecast the global nuclear medicine & radiopharmaceuticals market based on product, application, region. - To identify drivers and challenges for the global nuclear medicine & radiopharmaceuticals market. - To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global nuclear medicine & radiopharmaceuticals market. - To identify and analyze the profile of leading players operating in the global nuclear medicine & radiopharmaceuticals market. Why Choose This Report - Gain a reliable outlook of the global nuclear medicine & radiopharmaceuticals market forecasts from 2022 to 2028 across scenarios. - Identify growth segments for investment. - Stay ahead of competitors through company profiles and market data. - The market estimate for ease of analysis across scenarios in Excel format. - Strategy consulting and research support for three months. - Print authentication provided for the single-user license.